PMID- 34114395
OWN - NLM
STAT- MEDLINE
DCOM- 20220202
LR  - 20220202
IS  - 2589-451X (Electronic)
IS  - 0255-2922 (Linking)
VI  - 41
IP  - 3
DP  - 2021 Jun
TI  - Celastrol induces caspase-dependent apoptosis of hepatocellular carcinoma cells 
      by suppression of mammalian target of rapamycin.
PG  - 381-389
LID - 10.19852/j.cnki.jtcm.2021.03.006 [doi]
AB  - OBJECTIVE: To investigate the efficacy of celastrol treatment of hepatocellular 
      carcinoma (HCC) cells in vitro and in vivo and to propose a mechanism of action. 
      METHODS: A human HepG2 liver cancer cell line and a xenograft tumor model were 
      used to investigate the effects of celastrol on HCC in vitro and in vivo. A CCK-8 
      kit was used to detect cell viability. Flow cytometry and 
      terminal-deoxynucleoitidyl transferase mediated nick end labeling staining were 
      used to detect apoptosis. Western blotting and immunohistochemistry were used to 
      detect the expression of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9, 
      cleaved-PARP, mammalian target of rapamycin (mTOR), and p-mTOR. Hematoxylin-eosin 
      staining was used to observe the tissue morphology. RESULTS: Celastrol decreased 
      the viability of HepG2 cells and induced apoptosis. Western blot assays indicated 
      that celastrol up-regulated cleaved-caspase-3, cleaved-caspase-8, 
      cleaved-caspase-9, and cleaved-PARP by inhibiting the phosphorylation of mTOR in 
      HepG2 cells. Moreover, celastrol inhibited the tumor growth in a xenograft model. 
      Celastrol also induced caspase-dependent apoptosis (up-regulation of 
      cleaved-caspase- 3, -8, -9, and cleaved-PARP) and inhibited the activation of 
      mTOR in vivo. CONCLUSION: Celastrol induces caspase-dependent apoptosis in HCC 
      cells by inhibiting the activation of mTOR.
FAU - Shen, Bo
AU  - Shen B
AD  - Nanjing Integrated Traditional Chinese and Western Medicine Hospital Affiliated 
      to Nanjing University of Chinese Medicine, Nanjing 210014, China.
FAU - Chen, Hai-Bin
AU  - Chen HB
AD  - Science and Technology Department, Nanjing University of Chinese Medicine, 
      Nanjing 210023, China.
FAU - Zhou, Hong-Guang
AU  - Zhou HG
AD  - The First Clinical Medical College, Nanjing University of Chinese Medicine, 
      Nanjing 210023, China.
FAU - Wu, Mian-Hua
AU  - Wu MH
AD  - The First Clinical Medical College, Nanjing University of Chinese Medicine, 
      Nanjing 210023, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - J Tradit Chin Med
JT  - Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan
JID - 8211546
RN  - 0 (Pentacyclic Triterpenes)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - L8GG98663L (celastrol)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Apoptosis
MH  - *Carcinoma, Hepatocellular/drug therapy/genetics
MH  - Cell Line
MH  - Cell Line, Tumor
MH  - Cell Proliferation
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/genetics
MH  - Pentacyclic Triterpenes
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases/genetics
OTO - NOTNLM
OT  - Apoptosi
OT  - Carcinoma, hepatocellular
OT  - Caspase
OT  - Celastrol
OT  - mTOR
EDAT- 2021/06/12 06:00
MHDA- 2022/02/03 06:00
CRDT- 2021/06/11 07:16
PHST- 2021/06/11 07:16 [entrez]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2022/02/03 06:00 [medline]
AID - 3160 [pii]
AID - 10.19852/j.cnki.jtcm.2021.03.006 [doi]
PST - ppublish
SO  - J Tradit Chin Med. 2021 Jun;41(3):381-389. doi: 10.19852/j.cnki.jtcm.2021.03.006.